-
Vaccination for Patients With Immunosuppression and Altered Immunity: A Workgroup Report from the AAAAI Adverse Reactions to Drugs, Biologics, and Vaccines Committee and the Autoimmunity and Altered Immune Response Committee. J Allergy Clin Immunol Pract. 2026 Jul; 14(7):1549-1561.
Kwan M, Kaplan BM, Shaw K, Alix V, Hatcher VR, Shah I, Levy DS, Shabih M, Norton AE, Pandya A, Pope SM, Vaswani SK, Rosenblatt HM, Anvari S, Walter J, Jerath M, Lu HL, Engler R, Adams KE. PMID: 42409458.
View in:
PubMed Mentions: Fields:
Translation:
HumansPHPublic Health
-
Berotralstat, the first oral prophylaxis for hereditary angioedema in children aged 2 to 12 years: The kids are alright! Ann Allergy Asthma Immunol. 2025 Dec; 135(6):610-611.
Levy DS. PMID: 41297999.
View in:
PubMed Mentions: Fields:
-
Quality of life and burden of disease in patients with hereditary angioedema and their caregivers. Allergy Asthma Proc. 2025 09 01; 46(5):398-405.
Levy DS, Nagase FI, Cheung A, Rodeberg DA, Manning ME. PMID: 40958183.
View in:
PubMed Mentions:
2 Fields:
Translation:
Humans
-
Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study. Lancet Haematol. 2024 Jun; 11(6):e436-e447.
Craig TJ, Levy DS, Reshef A, Lumry WR, Martinez-Saguer I, Jacobs JS, Yang WH, Ritchie B, Aygören-Pürsün E, Keith PK, Busse P, Feuersenger H, Alexandru Bica M, Jacobs I, Pragst I, Magerl M. PMID: 38710185.
View in:
PubMed Mentions:
5 Fields:
Translation:
HumansCTClinical Trials
-
An expert panel's review on patients with hereditary angioedema switching from attenuated androgens to oral prophylactic therapy. Allergy Asthma Proc. 2024 01 01; 45(1):44-49.
Lumry WR, Bernstein JA, Li HH, Levy DS, Jones DH, Padilla BE, Li-Mcleod J, Tachdjian R. PMID: 38151740.
View in:
PubMed Mentions:
9 Fields:
Translation:
Humans
-
Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2022 03 05; 399(10328):945-955.
Craig T, Magerl M, Levy DS, Reshef A, Lumry WR, Martinez-Saguer I, Jacobs JS, Yang WH, Ritchie B, Aygören-Pürsün E, Keith PK, Busse P, Feuersenger H, Pawaskar D, Jacobs I, Pragst I, Doyle MK. PMID: 35219377.
View in:
PubMed Mentions:
27 Fields:
Translation:
Humans
-
Correction to: Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study. Orphanet J Rare Dis. 2021 Jul 28; 16(1):329.
Lumry WR, Zuraw B, Cicardi M, Craig T, Anderson J, Banerji A, Bernstein JA, Caballero T, Farkas H, Gower RG, Keith PK, Levy DS, Li HH, Magerl M, Manning M, Riedl MA, Lawo JP, Prusty S, Machnig T, Longhurst H, COMPACT Investigators. PMID: 34321052; PMCID: PMC8317315.
View in:
PubMed Mentions: Fields:
-
Letting the patients speak: an in-depth, qualitative research-based investigation of factors relevant to health-related quality of life in real-world patients with hereditary angioedema using subcutaneous C1 inhibitor replacement therapy. Allergy Asthma Clin Immunol. 2021 Jun 27; 17(1):60.
Anderson J, Levy DS, Lumry W, Koochaki P, Lanar S, Henry Li H. PMID: 34176500; PMCID: PMC8237414.
View in:
PubMed Mentions:
17
-
Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study. Orphanet J Rare Dis. 2021 02 15; 16(1):86.
Lumry WR, Zuraw B, Cicardi M, Craig T, Anderson J, Banerji A, Bernstein JA, Caballero T, Farkas H, Gower RG, Keith PK, Levy DS, Li HH, Magerl M, Manning M, Riedl MA, Lawo JP, Prusty S, Machnig T, Longhurst H, on behalf of the COMPACT Investigators. PMID: 33588897; PMCID: PMC7885603.
View in:
PubMed Mentions:
25 Fields:
Translation:
Humans
-
Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial. Allergy Asthma Clin Immunol. 2020; 16:8.
Levy DS, Farkas H, Riedl MA, Hsu FI, Brooks JP, Cicardi M, Feuersenger H, Pragst I, Reshef A. PMID: 32042283; PMCID: PMC7001333.
View in:
PubMed Mentions:
10
-
Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema. J Allergy Clin Immunol Pract. 2018 Sep - Oct; 6(5):1733-1741.e3.
Lumry WR, Craig T, Zuraw B, Longhurst H, Baker J, Li HH, Bernstein JA, Anderson J, Riedl MA, Manning ME, Keith PK, Levy DS, Caballero T, Banerji A, Gower RG, Farkas H, Lawo JP, Pragst I, Machnig T, Watson DJ. PMID: 29391286.
View in:
PubMed Mentions:
43 Fields:
Translation:
HumansCTClinical Trials
-
Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor. N Engl J Med. 2017 03 23; 376(12):1131-1140.
Longhurst H, Cicardi M, Craig T, Bork K, Grattan C, Baker J, Li HH, Reshef A, Bonner J, Bernstein JA, Anderson J, Lumry WR, Farkas H, Katelaris CH, Sussman GL, Jacobs J, Riedl M, Manning ME, Hebert J, Keith PK, Kivity S, Neri S, Levy DS, Baeza ML, Nathan R, Schwartz LB, Caballero T, Yang W, Crisan I, Hernandez MD, Hussain I, Tarzi M, Ritchie B, Králícková P, Guilarte M, Rehman SM, Banerji A, Gower RG, Bensen-Kennedy D, Edelman J, Feuersenger H, Lawo JP, Machnig T, Pawaskar D, Pragst I, Zuraw BL, COMPACT Investigators. PMID: 28328347.
View in:
PubMed Mentions:
78 Fields:
Translation:
HumansCTClinical Trials
-
IOP variation. Ophthalmology. 2006 Jul; 113(7):1253; author reply 1254.
Levy DS. PMID: 16815423.
View in:
PubMed Mentions: Fields:
Translation:
Humans